CLB - NYSE
Core Laboratories N.V.
$13.69
+0.66%Core Laboratories N.V. provides reservoir description and production enhancement services and products to the oil and gas industry in the United States, Canada, and internationally. It operates through Reservoir Description and Production Enhancement segments. The Reservoir Description segment includes the characterization of petroleum reservoir rock, reservoir fluid, and gas samples to enhance production and improve recovery of oil and gas from its clients' reservoirs. It offers laboratory-based analytical and field services to characterize properties of crude oil and oil delivered products; and proprietary and joint industry studies. The Production Enhancement segment provides services and products relating to reservoir well completions, perforations, stimulations, and production. It offers integrated diagnostic services to evaluate and monitor the effectiveness of well completions and to develop solutions to improve the effectiveness of enhanced oil recovery projects. In addition, the company markets and sells its products through a combination of sales representatives, technical seminars, trade shows, and print advertising, as well as through distributors. It operates approximately in 50 countries. The company was founded in 1936 and is based in Amstelveen, the Netherlands.
At a Glance
Live SnapshotCore Laboratories N.V. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Moderate conversion rate. Some gap between earnings and cash flow may warrant investigation into working capital or non-cash items.
CapEx Intensity
Moderate capital requirements typical of many stable businesses. Healthy balance between reinvestment and cash generation.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Moderate working capital outflow. Typical for growing businesses, but ensure it's supporting revenue growth, not inefficiency.
Cash Flow Quality Insight
Solid cash generation: Positive free cash flow with reasonable earnings quality provides financial flexibility for growth investments, debt reduction, or shareholder returns.
Core Laboratories N.V. Cash Flow Statement
CLB • NYSE
| Core Laboratories N.V. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | Dec 2007 | Dec 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | ||||||||||||||||||||
31.8M | 32.2M | 37M | 19.7M | 20.2M | -96.9M | 93.7M | 79.8M | 83.1M | 63.9M | 114.9M | 258.6M | 243.2M | 216.6M | 184.6M | 145.4M | 114.1M | 143.6M | 121.1M | 82.7M | |
14.6M | 15M | 15.8M | 17.2M | 18.5M | 20.9M | 22.6M | 23.1M | 24.9M | 26.9M | 27.5M | 26.7M | 25.5M | 22.9M | 23.3M | 23.3M | 24.3M | 21.8M | 19.5M | 17.7M | |
-4.7M | 674K | -10.8M | 433K | 6M | -12.2M | -36.3M | 1.8M | 9M | -14.4M | -107K | 4.7M | 6.8M | 3.6M | -6.5M | -10.1M | 25.6M | -1.4M | 6.1M | 8.1M | |
7.1M | 3.8M | 14M | 7.8M | 19.1M | 7.4M | 20.9M | 34.2M | 22.9M | 22.1M | 21.3M | 20.5M | 20.5M | 18.4M | 17.2M | 8.5M | 5.9M | 4.7M | 0.0 | 0.0 | |
-6.1M | -3M | -2.4M | 5M | -3M | 132.8M | -478K | -17.2M | -6.3M | -1.7M | 8.5M | -359K | -4.4M | -894K | 6.6M | 16.6M | 13.9M | -1.2M | -3.8M | 5.1M | |
(0.0) | (28.4M) | (29.1M) | (28.2M) | (18.1M) | (21.3M) | (13.8M) | (31.9M) | (24.3M) | (12.2M) | (35.5M) | (79.6M) | (57M) | (85.7M) | (74.7M) | (57.3M) | (41.7M) | (56.1M) | (0.0) | (0.0) | |
-5.6M | 7.9M | -28.8M | -25M | -24.3M | 5.9M | -10.8M | -9.9M | -9.4M | 35.2M | 47M | -6.7M | 6.6M | -23.4M | -21M | 22.2M | -2M | -12.3M | -17.2M | 6.8M | |
37.2M | 56.4M | 24.8M | 25M | 36.6M | 57.9M | 89.5M | 111.8M | 124.3M | 131.9M | 219.1M | 303.4M | 298.1M | 237.2M | 204.1M | 205.8M | 181.9M | 155.2M | 125.7M | 120.3M | |
INVESTING ACTIVITIES | ||||||||||||||||||||
(0.0) | -13M | -10.6M | -10.2M | -13.5M | -11.9M | -22.3M | -21.7M | -18.8M | -11.7M | -24.3M | -37.4M | -38.9M | -32.8M | -30.1M | -27.8M | -17.5M | -31.3M | -24.1M | -24.7M | |
-1.2M | (0.0) | (0.0) | (240K) | (873K) | (1.5M) | (3M) | -47.3M | (0.0) | -1.2M | -13.8M | -1.2M | -98K | -878K | -18.8M | -9M | -11.5M | -11.5M | -7.3M | (0.0) | |
(0.0) | (0.0) | (0.0) | (0.0) | (13.5M) | (0.0) | -1.9M | -1.3M | -2.1M | -2.5M | -2.9M | -4.3M | -6.6M | -3.3M | (0.0) | (0.0) | -1.6M | (0.0) | (0.0) | (0.0) | |
0.0 | 0.0 | 0.0 | 0.0 | 726K | 0.0 | 22.3M | 22.9M | 0.0 | 0.0 | 0.0 | 0.0 | 1.4M | 101K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
-994K | 6.6M | 3.9M | 6.1M | -11.8M | 18.2M | -6.8M | -23.2M | -18.5M | -11M | -22.9M | -36.6M | -37.9M | -29.9M | -33.2M | -29.6M | -16.9M | -29.6M | 11.5M | 1.1M | |
-2.2M | -6.4M | -6.7M | -3.9M | -10.2M | (7.9M) | -5.7M | -70.6M | -20.6M | -14.7M | -39.7M | -42.1M | -43.2M | -34M | -52M | -38.6M | -18.5M | -41.1M | -20M | -23.6M | |
FINANCING ACTIVITIES | ||||||||||||||||||||
-12.4M | -5.3M | -2.2M | -3.9M | 51.7M | -2.8M | -3.3M | -7.5M | -16.9M | 190M | -159.7M | -264.4M | -227.2M | -175.7M | -61.8M | -92.5M | -9.4M | -31.7M | -163.4M | -179.7M | |
-16.7M | -38M | -9M | -15M | -71M | -46M | 15M | 64M | 10M | -217.2M | 75.3M | 88.8M | 33M | 8.7M | 68.9M | -82.3M | 0.0 | -56.4M | 263K | 210.5M | |
-1.9M | -1.9M | -1.9M | -1.9M | -1.8M | -12.4M | -97.6M | -97.3M | -97.1M | -95.1M | -94.2M | -89.1M | -58.6M | -53M | -46M | -40M | -26.7M | -27.6M | (0.0) | (0.0) | |
-12.4M | -5.3M | -2.2M | -3.9M | -8.3M | -2.8M | -3.3M | -7.5M | -16.9M | -7.2M | -159.7M | -264.4M | -227.2M | -175.7M | -61.8M | -92.5M | -9.4M | -31.7M | -181.8M | -251.1M | |
-254K | -775K | -5.4M | -2.6M | -1.4M | -1.8M | 8K | -1.8M | -26K | -2.5M | -1.7M | 1.5M | 3.8M | 6.7M | -217.7M | -233K | 17.6M | 12.2M | 28.8M | -87M | |
-31.3M | -46M | -18.4M | -23.4M | -22.5M | -63M | -85.9M | -42.5M | -104.1M | -124.9M | -180.3M | -263.1M | -249.1M | -213.3M | -256.7M | -214.4M | -18.4M | -103.6M | -134.3M | -56.2M | |
CASH FLOW SUMMARY | ||||||||||||||||||||
3.7M | 4M | -308K | -2.3M | 3.9M | 2.7M | -2M | -1.3M | -364K | -7.7M | -856K | -1.7M | 5.9M | -10.1M | -104.5M | -47.2M | 144.9M | 10.5M | -28.6M | 40.5M | |
19.2M | 15.1M | 15.4M | 17.7M | 13.8M | 11.1M | 13.1M | 14.4M | 14.8M | 22.5M | 23.4M | 25.1M | 19.2M | 29.3M | 133.9M | 181M | 36.1M | 25.6M | 54.2M | 13.7M | |
22.8M | 19.2M | 15.1M | 15.4M | 17.7M | 13.8M | 11.1M | 13.1M | 14.4M | 14.8M | 22.5M | 23.4M | 25.1M | 19.2M | 29.3M | 133.9M | 181M | 36.1M | 25.6M | 54.2M | |
22.6M | 43.4M | 14.2M | 14.7M | 23M | 46M | 67.3M | 90.1M | 105.5M | 120.2M | 194.8M | 266M | 259.2M | 204.4M | 174M | 178M | 164.3M | 123.9M | 101.6M | 95.6M |
SEC Filings
CLB - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A N/A | April 28, 2023 | April 28, 2023 | ||
10-Q 10-Q 2023 Q1 Q1 | April 27, 2023 | March 31, 2023 | 2023 | |
8-K 8-K 2023 N/A | April 26, 2023 | April 26, 2023 | 2023 | |
8-K 8-K 2023 N/A | April 04, 2023 | April 03, 2023 | 2023 | |
10-K 10-K 2022 FY FY | February 10, 2023 | December 31, 2022 | 2022 | |
8-K 8-K 2023 N/A | February 03, 2023 | February 02, 2023 | 2023 | |
8-K 8-K 2023 N/A | February 01, 2023 | February 01, 2023 | 2023 | |
8-K 8-K 2023 N/A | January 17, 2023 | January 17, 2023 | 2023 | |
8-K 8-K 2022 N/A | November 04, 2022 | November 04, 2022 | 2022 | |
10-Q 10-Q 2022 Q3 Q3 | October 28, 2022 | September 30, 2022 | 2022 |
Related Guides
Continue your CLB research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.